论文部分内容阅读
慢性阻塞性气道疾患(COAD)患者中正越来越多地使用大剂量舒喘灵吸入。为了确定达到最佳支气管扩张所需剂量范围以及其中需用大剂量者所占比例进行了本研究。方法 COPD 患者23例,平均年龄56岁(38~82)岁,平均基础第一秒用力呼气量(FEV_1)为1.6(0.5~2.9)L。通过定量吸入器将舒喘灵以逐步增加的6个剂量(0.2~1.2mg)投予。结果当舒喘灵累积剂量达1.0mg和1.2mg 时 FEV_1上升至值2.0L。累积剂量为0.2mg、0.4mg、0.6mg 时,其平均 FEV_1上升与相应的前一剂量比较均具高度显著性(P<0.01)。再增加剂量对于进一步提高平均 FEV_1则缺乏显著性(0.6mg 与1.2mg,配对 t 检验 P>0.2)。尽管有5/23(22%)需用舒喘灵至>1mg,大部分患者14/23(61%)用≤0.6mg 即可获得90%最
Patients with chronic obstructive airway disease (COAD) are increasingly using high-dose inhaled salbutamol. This study was conducted to determine the range of doses required to achieve optimal bronchiectasis and the proportion of those who require high doses. Methods Twenty-three COPD patients with a mean age of 56 years (ranged from 38 to 82 years) had an average basis first-second forced expiratory volume (FEV_1) of 1.6 (0.5 to 2.9) L. Salbutamol was administered at a gradually increasing dose of 6 (0.2-1.2 mg) by a metered dose inhaler. Results When the cumulative dose of salbutamol 1.0mg and 1.2mg FEV_1 rose to the value of 2.0L. When the cumulative dose was 0.2mg, 0.4mg, 0.6mg, the average FEV_1 rise was highly significant compared with the corresponding previous dose (P <0.01). Additional doses did not significantly improve the mean FEV 1 (0.6 mg vs 1.2 mg, paired t-test P> 0.2). Although 5/23 (22%) required salbutamol to> 1 mg, the majority of patients achieved 90%